These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35656931)

  • 1. Association of Gender With Clinical Outcomes in a Contemporary Cohort of Patients With Atrial Fibrillation Receiving Oral Anticoagulants.
    Kim M; Kim J; Kim JB; Park J; Park JK; Kang KW; Shim J; Choi EK; Lee YS; Park HW; Joung B
    Korean Circ J; 2022 Aug; 52(8):593-603. PubMed ID: 35656931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke and Systemic Thromboembolism according to CHA
    Lee KB; Kim TH; Park J; Park JK; Kang KW; Kim J; Park HW; Choi EK; Kim JB; Lee YS; Shim J; Joung B
    Yonsei Med J; 2022 Apr; 63(4):317-324. PubMed ID: 35352882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation.
    O'Brien EC; Holmes DN; Thomas LE; Fonarow GC; Allen LA; Gersh BJ; Kowey PR; Singer DE; Ezekowitz MD; Naccarelli GV; Ansell JE; Chan PS; Mahaffey KW; Go AS; Freeman JV; Reiffel JA; Peterson ED; Piccini JP; Hylek EM
    Circulation; 2018 Aug; 138(9):889-897. PubMed ID: 29678813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Steinberg BA; Peterson ED; Kim S; Thomas L; Gersh BJ; Fonarow GC; Kowey PR; Mahaffey KW; Sherwood MW; Chang P; Piccini JP; Ansell J;
    Circulation; 2015 Feb; 131(5):488-94. PubMed ID: 25499873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
    Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
    Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
    Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
    Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening.
    Gibbs H; Freedman B; Rosenqvist M; Virdone S; Mahmeed WA; Ambrosio G; Camm AJ; Jacobson B; Jerjes-Sanchez C; Kayani G; Oto A; Panchenko E; Ragy H; Kakkar AK;
    Am J Med; 2021 Jul; 134(7):893-901.e11. PubMed ID: 33607088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
    Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry.
    Piccini JP; Simon DN; Steinberg BA; Thomas L; Allen LA; Fonarow GC; Gersh B; Hylek E; Kowey PR; Reiffel JA; Naccarelli GV; Chan PS; Spertus JA; Peterson ED;
    JAMA Cardiol; 2016 Jun; 1(3):282-91. PubMed ID: 27438106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.
    Böhm M; Brueckmann M; Eikelboom JW; Ezekowitz M; Fräßdorf M; Hijazi Z; Hohnloser SH; Mahfoud F; Schmieder RE; Schumacher H; Wallentin L; Yusuf S
    Eur Heart J; 2020 Aug; 41(30):2848-2859. PubMed ID: 32385506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
    Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Steinberg BA; Kim S; Piccini JP; Fonarow GC; Lopes RD; Thomas L; Ezekowitz MD; Ansell J; Kowey P; Singer DE; Gersh B; Mahaffey KW; Hylek E; Go AS; Chang P; Peterson ED;
    Circulation; 2013 Aug; 128(7):721-8. PubMed ID: 23861512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.